FFPE: The Workhorse Behind NGS Testing

Labcorp, Rebecca Previs, Kyle Strickland, Erin Newburn, biomarker, sequencing, diagnostics, translational research, precision

Exploring FFPE’s impact on precision oncology, NGS innovation, and the future of tissue stewardship in cancer care with leading Labcorp experts.

Jan 28^th • 33 mins listen

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Highlights From Today’s Episode “With next-generation sequencing (NGS), multiple biomarkers can be evaluated using one test. So, in cancer care, we’re learning that any given tumor may harbor a variety of variants. So, if we’re considering using in situ hybridization (ISH)…

Mar 30^th • 47 mins listen

Oncology Pharmacology 2023: Today’s Treatments and Tomorrow’s Breakthroughs

CDER, FDA, Nurses, biomarker, immunomodulatory

Highlights From Today’s Episode “Full approval through the Center for Drug Evaluation and Research (CDER) and FDA means that those drugs have gone through the laboratory testing, human clinical trial testing, and very extensive clinical trials to make sure that they are effective and th…

Mar 30^th • 53 mins listen